Photocure Partner Asieris announces completion of enrollment for Hexvix Phase III clinical trial in China
Press Release – Oslo, Norway, July 6, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that it has completed patient enrollment for the Hexvix[®] Phase III bridging trial.The objective of the multicenter Phase III trial is to support regulatory approval of Hexvix in Mainland China. The bridging trial is intended to confirm results from prior clinical trials regarding the safety and detection benefits of blue light cystoscopy (BLC[®]) with Hexvix compared to white light cystoscopy in the